Journal article
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease
S Gauthier, H Feldman, J Hecker, B Vellas, D Ames, P Subbiah, E Whalen, B Emir, PJ Albarède, RJ Ancill, S Atallah, P Bailey, SE Black, MJ Borrie, K Boundy, R Clarnette, S Cohen, DG Darby, M Ewer, K Farcnik Show all
International Psychogeriatrics | CAMBRIDGE UNIV PRESS | Published : 2002
Abstract
Objective: This subanalysis of a large, double-blind, placebo-controlled trial examined the prevalence of behavioral symptoms in moderate to severe Alzheimer's disease (AD), and the effect of treatment with donepezil. Methods: Two hundred ninety patients with moderate to severe AD (standardized Mini-Mental State Examination scores 5-17) were randomized to receive 24 weeks of once-daily doses of donepezil 5 mg/day for 28 days, and 10 mg/day thereafter per the clinician's judgment (n = 144), or placebo (n = 146). The outcome measure of interest was the 12-item Neuropsychiatric Inventory (NPI). Results: Baseline demographics were similar between the treatment groups. Least squares mean (± SE) b..
View full abstract